1. Inicio
  2. Publicaciones
  3. Effect of N-Acetylcysteine on Bronchiectasis in a Real-life Study. Data From the Spanish RIBRON Registry

Effect of N-Acetylcysteine on Bronchiectasis in a Real-life Study. Data From the Spanish RIBRON Registry

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Olveira, C
  • Girón, R
  • García-Clemente, M
  • Máiz, L
  • Sibila, O
  • Golpe, R
  • Rodríguez-Hermosa, J
  • Barreiro, E
  • Prados, C
  • Rodríguez-López, JL
  • de la Rosa-carrillo, D

Grupos

Abstract

Introduction: There is scarce information about the most used mucolytic drug in bronchiectasis Nacetylcysteine (N-AC). Our objective was to analyze the effect of N-AC with respect to some outcomes in bronchiectasis. Methods: Ambispective, longitudinal, observational, multi-center (43 centers) study of a cohort of 2461 adult patients diagnosed with bronchiectasis. Those patients treated in a stable situation with at least 600 mg/d of N-AC (368; 15%) for at least 6 months were compared with patients not receiving this treatment. The variables analyzed and compared were those available two years before and after treatment. ANCOVA analysis was used to analyze the effect of N-AC as the inter-group difference of the basal intra-group difference for each variable, adjusted for relevant covariables. Results: The N-AC group showed a full adjusted improvement of 27% in exacerbations, 17% in hospitalizations, and 31% in total exacerbation rates compared with the no-N-AC group. Moreover, a decrease in the volume of sputum production of 59.7% was observed as well as a decrease of 12% of patients with bronchial infection by Pseudomonas aeruginosa (PA). The use of 1200 mg/d (n = 116) resulted in only a mild, albeit significative improvement in the exacerbation rate compared with the use of 600 mg/d (-11% in absolute number). Both doses were well tolerated. Conclusion: N-AC (in most cases at a dose of 600 mg/d) is safe and effective and sufficient to reduce both the number of exacerbations and hospitalizations and the purulence and volume of sputum, as well as the isolation rate of PA in patients with bronchiectasis.<br /> (c) 2025 SEPAR. Published by Elsevier Espana, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Copyright © 2025 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0300-2896, 1579-2129

ARCHIVOS DE BRONCONEUMOLOGIA  ELSEVIER ESPANA SLU

Tipo:
Article
Páginas:
196-202
PubMed:
40180519
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,262 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Bronchiectasis; Mortality; Exacerbations; Hospitalizations; Pseudomonas aeruginosa

Cita

Compartir